The 'Goldilocks' Case For Baxter International

Baxter International's stock has been challenging to own for the past decade, initially due to high valuations and later due to execution concerns and an ugly acquisition. During the pandemic, health care stocks, including Baxter, underperformed expectations, with BAX peaking in April 2020 before declining. But the divestiture of the kidney care business will help the balance sheet, and management is optimistic toward 2025 performance....

Seeking Alpha - 5/8/2025 10:16:09 AM More News for BAX
Stock Analysis for BAX
Related Stocks: